Thank you, Richard. And let me first turn to the pipeline, where CAM2029 remains the central near-term value driver for us. So CAM2029 is a broad opportunity built around a long-acting octreotide with potential across acromegaly, gastroenteropancreatic neuroendocrine tumours, and polycystic liver disease. The key point is that this is not a single indication asset. It is a drug compound and delivery platform with multiple clinically validated opportunities beyond acromegaly. The ACROINNOVA 1 programme is completed and it is being communicated at various medical conferences and elsewhere. Oczyesa is approved in the UK and EU, and the European launch is underway. The FDA issued a complete response letter for Oczyesa in June. Importantly, this relates to observations during a previous GMP manufacturing inspection at the third-party site and not to the efficacy or safety profile of CAM2029. Those observations have now been addressed, and a new PDUFA target action date is the next important regulatory milestone for the programme. Our view of the clinical profile and commercial opportunity for CAM2029 remains unchanged. Our largest near-term opportunity, though, is gastroenteropancreatic neuroendocrine tumours, a substantial and growing market with considerable unmet medical needs. SORENTO is the largest randomized study of a somatostatin receptor ligand in GEP-NET to date and is our most important pipeline catalyst this year. The study has been fully enrolled since the end of 2023, and based on current event accrual, we expect to reach the target of 194 progression-free survival events in the fourth quarter, followed by the readout of primary results. A positive outcome for CAM2029 in NET would support the compound as a new first-line treatment option, opening a very meaningful new growth avenue for Camurus. Finally, in polycystic liver disease, the positive POSITANO phase two results were presented and recognized at this year. EASL conference in Barcelona, a leading hepatology event. We hold orphan drug designations in the US and EU for PLD and ADPKD, and have completed the FDA end-of-Phase 2 meeting this year; the extension study is currently ongoing, which, together with the feedback, will form the basis for the decision around the continued Phase 3 programme. Beyond CAM2029. Our earlier-stage pipeline gives us additional exposure to large therapeutic areas, while allowing us to leverage the same long-acting delivery experience that underpins our commercial portfolio. CAM2056 is our once-monthly semaglutide depot based on the FluidCrystal technology. During the quarter, we completed a Type B meeting with the FDA, and the regulatory submission package for the Phase 2b clinical trial has been prepared. The study remains on track to start in the second half of the year. Building on the positive phase 1b data reported in November, product design work is also ongoing in parallel, including validation of an autoinjector pen to support simple, once-monthly dosing. We see a meaningful opportunity for once-monthly incretin therapies overall, particularly given the adherence challenges seen for current weekly and daily treatments. Our collaboration with Eli Lilly is progressing to plan. During the quarter, Lilly exercised its option to include amylin agonists, expanding the scope of the partnership beyond the dual and triple incretin agonists that we had already started. We. We view this as a further external validation of the FluidCrystal technology and its potential in the long-acting metabolic medicine space. With Gubra, we have selected the lead compound for our long-acting parathyroid hormone analogue program and are advancing into further development. Taken together, these programs provide several independent opportunities to create value across large and underserved therapeutic areas, supported by our own development capabilities and two well-resourced partners. Let me close with a brief quarterly summary and the priorities ahead.
Our strategy rests on four clear priorities: first, commercial execution, extending our leadership in the opioid dependence area with Buvidal and Brixadi and advancing the Oczyesa launch in Europe, strengthening the readiness and broadening the CAM2029 commercial efforts.
Second, advancing our pipeline with multiple near-term catalysts. The SORENTO readout in GEP-NET, the start of the CAM2056 phase 2b trial, and the US resubmission pathway for Oczyesa, alongside progress in the broader portfolio. Third, partnerships and business development. We are progressing our collaborations with Eli Lilly and Gubra, and we remain active in evaluating opportunities that can broaden our pipeline and add long-term value for the company; and fourth, financial strength. We have been sustainably profitable since 2022 and ended the quarter with 4.1 billion Swedish kronor in net cash, giving us the means to invest behind our launches, pipeline, and business development opportunities, while maintaining strategic flexibility. The second quarter showed our model is working with record product sales, strong profitability, disciplined investment, and a robust balance sheet.
We now enter a catalyst-rich second half with clear priorities: commercial execution, pipeline advancement, and selective capital deployment with strong momentum across the business. We are well-positioned to continue creating value for patients and, of course, also for shareholders. And with that said, we are ready for the first question.